BIOCHEMICAL AND PHARMACOLOGIC RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE
Tóm tắt
Từ khóa
Tài liệu tham khảo
CASU, B. Methods of structural analysis. In: Heparin: Chemical and Biological Properties, Clinical Applications. D.A. Lane and U. Lindahl (eds.), pp. 25–50, Edward Arnold, London (1989).
ABILDGAARD, 1968, Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis, Scand J Clin Lab Invest, 21, 89, 10.3109/00365516809076981
ANDERSSON, 1976, Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration, Thromb Res, 9, 575, 10.1016/0049-3848(76)90105-5
HÖÖK, 1976, Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin, FEBS Lett, 66, 90, 10.1016/0014-5793(76)80592-3
LAM, 1976, The separation of active and inactive forms of heparin, Biochem Biophys Res Commun, 69, 570, 10.1016/0006-291X(76)90558-1
HOLMER, 1981, The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin, Biochem J, 193, 395, 10.1042/bj1930395
LAURENT, 1978, The molecular weight dependence of the anticoagulant activity of heparin, Biochem J, 175, 691, 10.1042/bj1750691
OOSTA, 1981, Multiple functional domains of the heparin molecule, Proc Natl Acad Sci USA, 78, 829, 10.1073/pnas.78.2.829
BARROWCLIFFE, T.W., JOHNSON, E.A., EGGLETON, C.A., KEMBALL-COOK, G. and THOMAS, D.P. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 41, 573–83, 1979.
CHOAY, 1980, Anti-Xa active heparin oligosaccharides, Thromb Res, 18, 573, 10.1016/0049-3848(80)90356-4
CARTER, 1981, Relationship between the anti-thrombotic and anticoagulant effects of low molecular weight heparin, Thromb Res, 21, 169, 10.1016/0049-3848(84)90045-8
HOLMER, 1982, Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits, Thromb Res, 25, 475, 10.1016/0049-3848(82)90089-5
OCKELFORD, 1982, Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction, Thromb Res, 28, 401, 10.1016/0049-3848(82)90121-9
THOMAS, 1981, Studies in man and experimental animals of a low molecular weight heparin fraction, Thromb Haemost, 45, 214, 10.1055/s-0038-1650173
THOMAS, 1982, Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis, Thromb Haemost, 47, 244, 10.1055/s-0038-1657178
CHOAY, 1981, Structural studies on a biologically active hexasaccharide obtained from heparin, Ann NY Acad Sci, 370, 644, 10.1111/j.1749-6632.1981.tb29770.x
THUNBERG, 1982, Further characterization of the antithrombin-binding sequence in heparin, Carbohydr Res, 100, 393, 10.1016/S0008-6215(00)81050-2
LINDAHL, 1979, Structure of the antithrombin-binding site of heparin, Proc Natl Acad Sci USA, 76, 3198, 10.1073/pnas.76.7.3198
CHOAY, 1983, Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity, Biochem Biophys Acta, 116, 492
ROSENBERG, 1979, Correlation between structure and function of heparin, Proc Natl Acad Sci USA, 76, 1218, 10.1073/pnas.76.3.1218
SINÄY, 1984, Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III, Carbohydr Res, 132, C5, 10.1016/0008-6215(84)85236-2
ATHA, 1985, Contribution of monosaccharide residues in heparin binding to antithrombin III, Biochemistry, 24, 6723, 10.1021/bi00344a063
TORRI, 1985, Mono- and bidimensional 500 MHZ proton NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: Evidence for conformational peculiarity of the sulfated iduronate residue, Biochem Biophys Res Commun, 128, 134, 10.1016/0006-291X(85)91655-9
LINDAHL, 1983, The antithrombin-binding sequence in heparin. Identification of an essential 6-0 sulfate group, J Biol Chem, 258, 9826, 10.1016/S0021-9258(17)44572-8
RIESENFELD, 1981, The antithrombin-binding sequence of heparin. Location of essential N-sulfate groups, J Biol Chem, 256, 2389, 10.1016/S0021-9258(19)69792-9
PETITOU, 1987, Synthesis of heparin fragments: A α-methyl alpha-pentaoside with high affinity for antithrombin III, Carbohydr Res, 167, 67, 10.1016/0008-6215(87)80268-9
PETITOU, 1991, A new synthetic pentasaccharide with increased anti-factor Xa activity: Possible role for anionic clusters in the interaction of heparin and antithrombin III, Semin Thromb Hemost, 17, 143
PETITOU, 1992, Chemical synthesis of heparin fragments and analogues, Prog Chem Org Nat Prod, 60, 143
RAGAZZI, 1987, Conformation of the pentasaccharide corresponding to the binding site of heparin to antithrombin-III, Carbohyr Res, 165, C1, 10.1016/0008-6215(87)80093-9
RAGAZZI, 1990, Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III, Carbohydr Res, 195, 169, 10.1016/0008-6215(90)84165-Q
CASU, 1981, The structure of heparin oligosaccharide fragments with anti-factor Xa activity containing the minimal antithrombin III-binding sequence, Biochem J, 197, 599, 10.1042/bj1970599
GETTINS, 1989, Examination by 1H-n.m.r. spectroscopy of the binding of a synthetic, high-affinity heparin pentasaccharide to human antithrombin III, Carbohydr Res, 185, 69, 10.1016/0008-6215(89)84022-4
PETITOU, 1984, Synthetic heparin fragments: new and efficient tools for the study of heparin and its interactions, Nouv Rev Fr Hematol, 26, 221
PETITOU, 1988, Binding of heparin to antithrombin III: A chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-d-glucose residue, Carbohydr Res, 179, 163, 10.1016/0008-6215(88)84116-8
WALENGA, J.M. Doctoral thesis: Factor Xa Inhibition in Mediating Antithrombotic Actions: Application of a Synthetic Heparin Pentasaccharide. Mention tres bien. Universite Pierre et Marie Curie, Paris VI, Paris, France, June 1987.
WALENGA, 1988, Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity, Thromb Res, 52, 553, 10.1016/0049-3848(88)90128-4
VAN BOECKEL, 1985, Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin, J Carbohydr Chem, 4, 293, 10.1080/07328308508070182
PETITOU, 1993, A new synthetic pentasaccharide with increased anti-factor Xa activity: Possible role for anionic clusters in the interaction of heparin and antithrombin III, Semin Thromb Res, 19, 143
VISSER, 1991, The AT-III binding affinities of a series of synthetic pentasaccharide analogues, Thromb Haemost, 65, 1296
MEULEMAN, 1991, Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: Discovery of compounds with a longer duration of action than of the natural pentasaccharide, Semin Thromb Hemost, 17, 112
VAN AMSTERDAM, 1995, Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times, Arterioscler Thromb Vasc Biol, 15, 495, 10.1161/01.ATV.15.4.495
HERAULT, 1995, Biochemical and pharmacological properties of O-sulfated, O-methylated analogues of the natural pentasaccharide, Thromb Haemost, 73, 1321
HERBERT, 1995, Biochemical and pharmacological properties of SANORG 32701, a potent analogue of the ‘natural pentasaccharide.’, Thromb Haemost, 73, 1321
CHANDRA, 1983, Isolation and sequence characterization of a cDNA clone of human antithrombin III, Proc Natl Acad Sci USA, 80, 1845, 10.1073/pnas.80.7.1845
CONARD, 1983, Molar antithrombin concentration in normal human plasma, Haemostasis, 13, 363
ROSENBERG, 1973, The purification and mechanism of action of human antithrombin-heparin cofactor, J Biol Chem, 248, 6490, 10.1016/S0021-9258(19)43472-8
JORDAN, 1980, The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin, J Biol Chem, 255, 10081, 10.1016/S0021-9258(19)70431-1
BRENNAN, 1988, New carbohydrate site in mutant antithrombin (7ILE-ASN) with decreased heparin affinity, FEBS Lett, 237, 118, 10.1016/0014-5793(88)80183-2
OLSON, 1992, Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions, J Biol Chem, 267, 12528, 10.1016/S0021-9258(18)42309-5
BJÖRK, I. and DANIELSSON, A. Antithrombin and related inhibitors of coagulation proteinases. In: Proteinase Inhibitors. A.J. Barrett and G.S. Salvesen (eds.), pp. 489–513, Elsevier, Amsterdam, The Netherlands (1986).
PETERSON, 1987, Antithrombin conformation and the catalytic role of heparin II. Is the heparin-induced conformational change in antithrombin required for rapid inactivation of thrombin, J Biol Chem, 262, 7559, 10.1016/S0021-9258(18)47602-8
NESHEIM, 1986, Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity purified heparin, J Biol Chem, 261, 3214, 10.1016/S0021-9258(17)35770-8
HOYLAERTS, 1984, Involvement of heparin chain length in the heparin catalyzed inhibition of thrombin by antithrombin III, J Biol Chem, 259, 5670, 10.1016/S0021-9258(18)91066-5
GRIFFITH, 1982, The heparin-enhanced antithrombin III/thrombin reaction is saturable with respect to both thrombin and antithrombin III, J Biol Chem, 257, 13899, 10.1016/S0021-9258(19)45315-5
GRIFFITH, 1985, Reactive site peptides structural similarity between heparin cofactor II and antithrombin III, J Biol Chem, 260, 2218, 10.1016/S0021-9258(18)89541-2
LORMEAU, 1995, The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to AT-mediated neutralization of factor Xa., Thromb Haemost, 74, 1474, 10.1055/s-0038-1649968
KAISER, 1993, Heparin cofactor II interactions with heparin pentasaccharide are minimal to mediate its antithrombotic actions, Thromb Haemost, 69, 1111
WALENGA, 1985, Preliminary biochemical and pharmacological studies on a chemically synthesized pentasaccharide, Semin Thromb Hemost, 11, 89, 10.1055/s-2007-1004364
BENDAYAN, 1994, Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins, Thromb Haemost, 71, 576, 10.1055/s-0038-1642485
BENDETOWICZ, 1990, The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma, Thromb Res, 58, 445, 10.1016/0049-3848(91)90249-V
HEMKER, 1989, Free factor Xa is on the main pathway of thrombin generation in clotting plasma, Biochem Biophys Acta, 992, 409, 10.1016/0304-4165(89)90107-4
EISENBERG, 1993, Importance of factor Xa in determining the procoagulant activity of whole-blood clots, J Clin Invest, 91, 1877, 10.1172/JCI116404
CADROY, 1993, Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in nonhuman primates, Thromb Haemost, 70, 631, 10.1055/s-0038-1649640
HÉRAULT, 1996, Comparative effects of two factor Xa inhibitors on prothrombinase assembled in different environments, Haemostasis, 26, S3
WALENGA, 1987, Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges, Thromb Res, 46, 187, 10.1016/0049-3848(87)90280-5
WALENGA, 1991, AT III as a rate limiting factor for the measurement of pentasaccharide in laboratory assays, Thromb Haemost, 65, 1314
BONEU, 1995, Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man, Thromb Haemost, 74, 1468, 10.1055/s-0038-1649967
WALENGA, 1988, The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity, Thromb Res, 51, 23, 10.1016/0049-3848(88)90279-4
DOL, 1993, The antithrombotic activity of synthetic pentasaccharides and fraxiparine is closely correlated with their respective ability to alter thromboplastin-triggered thrombin generation ex vivo, Thromb Haemost, 69, 655
WALENGA, 1991, Relative contribution of factor Xa and factor IIa inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharides, Thromb Haemorr Dis, 3, 53
OFOSU, 1990, Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma, Eur J Biochem, 193, 485, 10.1111/j.1432-1033.1990.tb19363.x
BÉGUIN, 1989, The action of a synthetic pentasaccharide on thrombin generation in whole plasma, Thromb Haemost, 61, 397, 10.1055/s-0038-1646603
LORMEAU, 1993, Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin, and a synthetic AT-III binding pentasaccharide, Thromb Haemost, 69, 152, 10.1055/s-0038-1651572
OFOSU, 1991, Modulation of the enzymatic activity of α-thrombin by polyanions: Consequences on intrinsic activation of factor V and factor VIII, Haemostasis, 21, 240, 10.1055/s-2007-1000399
WUN, 1992, Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides, Blood, 79, 430, 10.1182/blood.V79.2.430.430
JESKE, W. Doctoral thesis: Pharmacologic studies on synthetic analogues of heparin with selective affinity to endogenous serine protease inhibitors. Loyola University Chicago, Chicago, IL, May 1996.
RAO, 1993, Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa, Blood, 81, 2600, 10.1182/blood.V81.10.2600.2600
OFOSU, 1992, The low molecular weight heparin enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery, Br J Haematol, 83, 391
GEROTZIAFAS, 1996, Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood, Thromb Res, 81, 491, 10.1016/0049-3848(96)00022-9
LORMEAU, 1996, Antithrombin mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to AT, Thromb Haemost, 76, 5, 10.1055/s-0038-1650512
BROZE, 1988, Lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action, Blood, 71, 335, 10.1182/blood.V71.2.335.335
JESTY, 1996, Initiation of the tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor, Blood, 87, 2301, 10.1182/blood.V87.6.2301.bloodjournal8762301
HOPPENSTEADT, 1994, TFPI antigen levels in normal human volunteers after IV and SC administration of heparin and a low molecular weight heparin, Thromb Res, 77, 175, 10.1016/0049-3848(95)91623-S
BARA, 1993, Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor, Thromb Res, 69, 443, 10.1016/0049-3848(93)90233-E
LINDAHL, A.K., SANDSET, P.M. and ABILDGAARD, U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 3, 439–49, 1992.
WUN, 1992, Lipoprotein associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides, Blood, 79, 430, 10.1182/blood.V79.2.430.430
ZITOUN, 1994, Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits, Thromb Res, 75, 577, 10.1016/0049-3848(94)90232-1
LOJEWSKI, 1993, Molecular weight dependence on the release of tissue factor pathway inhibitor after subcutaneous and intravenous actions of heparins, Thromb Haemost, 69, 1174
KAISER, 1994, Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans, Thromb Res, 75, 609, 10.1016/0049-3848(94)90173-2
BERNAT, 1996, The synthetic pentasaccharide SR 90107A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits, Fibrinolysis, 10, 151, 10.1016/S0268-9499(96)80026-9
KAISER, 1996, Effect of unfractionated heparin and a heparin pentasaccharide on the thrombolytic process in an experimental model in rabbits, Fibrinolysis, 10, 127
FAREED, J., HOPPENSTEADT, D., JESKE, W. and WALENGA, J.M. An overview of nonheparin glycosaminoglycans as antithrombotic agents. In: Recent Advances in Blood Coagulation. L. Poller (ed.), pp. 169–187, Churchill Livingstone, London (1993).
SALZMAN, 1980, Effect of heparin and heparin fractions on platelet aggregation, J Clin Invest, 65, 64, 10.1172/JCI109661
LABROUCHE, 1992, Influence of selected heparins on human neutrophil functions in vitro, Thromb Haemost, 68, 556, 10.1055/s-0038-1646317
WALLIS, 1994, Active surveillance for heparin-induced thrombocytopenia or thromboembolism, Chest, 106, 120S
BRACE, 1986, Heparin-induced platelet aggregation: Dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions, Thromb Res, 42, 769, 10.1016/0049-3848(86)90113-1
MESSMORE, 1989, In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets, Ann NY Acad Sci, 556, 217, 10.1111/j.1749-6632.1989.tb22505.x
WALENGA, 1996, Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents, Clin Appl Thromb/Hemostasis, 2, S21
ELALAMY, 1995, Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia, Thromb Haemost, 74, 1384, 10.1055/s-0038-1649949
GREINACHER, 1995, Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia, Thromb Haemost, 74, 886, 10.1055/s-0038-1649842
PIFARRÉ, 1993, Comparative heparin induced thrombocytopenic response with low molecular weight heparin and a synthetic pentasaccharide, Thromb Haemost, 69, 1319
JESKE, 1996, Development of a flow cytometric assay for the detection of heparin induced thrombocytopenia, Blood, 88, 317a
WESSLER, 1959, Biologic assay of a thrombosis-inducing activity in human serum, J Appl Physiol, 14, 943, 10.1152/jappl.1959.14.6.943
WALENGA, 1986, Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model, Thromb Res, 43, 243, 10.1016/0049-3848(86)90066-6
THOMAS, 1989, The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model, Thromb Haemost, 61, 204, 10.1055/s-0038-1646559
AMAR, 1990, Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: An experimental study in two models of thrombosis in the rabbit, Br J Haematol, 76, 94, 10.1111/j.1365-2141.1990.tb07842.x
HOBBELEN, 1990, Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats, Thromb Haemost, 63, 265, 10.1055/s-0038-1645206
BUCHANAN, 1985, The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin, Blood, 65, 198, 10.1182/blood.V65.1.198.bloodjournal651198
CADE, 1985, A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation, Thromb Res, 35, 613, 10.1016/0049-3848(84)90265-2
BERGQVIST, 1985, The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis, Thromb Res, 38, 589, 10.1016/0049-3848(85)90202-6
RAAKE, 1989, Rat jugular vein hemostasis—A new model for testing antithrombotic agents, Thromb Res, 53, 73, 10.1016/0049-3848(89)90116-3
VOGEL, 1989, Comparison of two experimental thrombosis models in rats, effects of four glycosaminoglycans, Thromb Res, 54, 399, 10.1016/0049-3848(89)90210-7
VOGEL, 1993, Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt, Thromb Haemost, 69, 29, 10.1055/s-0038-1651543
WEICHERT, 1988, Effect of low molecular weight heparins on laser-induced thrombus formation in rat mesenteric vessels, Haemostasis, 18, 55
BERNAT, 1996, Protamine sulfate inhibits pentasaccharide (SR 80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat, Haemostasis, 26, 195
RACANELLI, A. Doctoral thesis: Biochemical and pharmacological studies on the interactions of protamine with heparins. Loyola University Chicago, Chicago, IL, January 1990.
YOUNG, 1994, Ex-vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin, Thromb Haemost, 71, 300, 10.1055/s-0038-1642434
BACHER, 1991, Endogenous AT III as a limiting factor in the mediation of antiprotease actions of heparins and related oligosaccharides. Impact on the pharmacodynamic parameters as calculated by using functional methods, Thromb Haemost, 65, 932
CRÉPON, 1993, Pharmacokinetic (PK) parameters of AT binding pentasaccharides in three animal species: Predictive value for humans, Thromb Haemost, 69, 654
HARA, 1994, DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor of factor Xa, Thromb Haemost, 71, 314, 10.1055/s-0038-1642436
OSTREM, 1995, Characterization of an orally available and highly specific synthetic factor Xa inhibitor, Thromb Haemost, 73, 1306
GIRARD, 1989, Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor, Nature, 338, 518, 10.1038/338518a0
HUANG, 1993, Kinetics of factor Xa inhibition by tissue factor pathway inhibitor, J Biol Chem, 268, 26950, 10.1016/S0021-9258(19)74202-1
DUNWIDDIE, 1989, Antistasin, a leech-derived inhibitor of factor Xa, J Biol Chem, 264, 16694, 10.1016/S0021-9258(19)84761-0
TUSZYNSKI, 1987, Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation, J Biol Chem, 262, 9718, 10.1016/S0021-9258(18)47993-8
VLASUK, 1991, Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis, Thromb Haemost, 65, 257, 10.1055/s-0038-1648131
RAGOSTA, 1994, Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits, Circulation, 89, 1262, 10.1161/01.CIR.89.3.1262
THEUNISSEN, 1994, Mutational analysis of antistasin, an inhibitor of blood coagulation factor Xa from the Mexican leech Haementeria officinalis, Thromb Res, 75, 41, 10.1016/0049-3848(94)90138-4
FAREED, J. Basic and applied pharmacology of low molecular weight heparins. Pharmacy Therapeut June, 16s–24s, 1995.
FAREED, 1989, Biochemical and pharmacological inequivalence of low molecular weight heparins, Proc Natl Acad Sci USA, 556, 333, 10.1111/j.1749-6632.1989.tb22515.x
CARRIE, 1994, Pharmacokinetic and pharmacodynamic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with CY216, Blood, 84, 2571, 10.1182/blood.V84.8.2571.2571
BOCK, 1985, Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene, Am J Hum Genet, 37, 32
BORG, 1988, Proposed heparin binding site in antithrombin based on arginine 47, J Clin Invest, 81, 1292, 10.1172/JCI113447
CHANG, 1986, Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity, J Biol Chem, 261, 1174, 10.1016/S0021-9258(17)36071-4
ERDJUMENT, 1988, Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow, J Biol Chem, 263, 5589, 10.1016/S0021-9258(18)60605-2
MILLE, 1994, Role of N- and C-terminal aminoacids in antithrombin binding to pentasaccharide, J Biol Chem, 269, 29435, 10.1016/S0021-9258(18)43898-7
OLSON, 1993, Parallel mechanisms of high molecular weight kininogen action as a cofactor in kallikrein inactivation and prekallikrein activation reactions, Biochemistry, 32, 12148, 10.1021/bi00096a027
LINDAHL, 1994, More to “heparin” than anticoagulation, Thromb Res, 75, 1, 10.1016/0049-3848(94)90136-8